Mary Grey Maher, MD
Associate Professor of UrologyCards
Appointments
Additional Titles
ERAS Lead, Urology
Homeostasis Course Lead, Urology
Faculty Lecture Series Contributor, Urology
Contact Info
Urology
PO Box 208058
New Haven, CT 06520-8058
United States
Appointments
Additional Titles
ERAS Lead, Urology
Homeostasis Course Lead, Urology
Faculty Lecture Series Contributor, Urology
Contact Info
Urology
PO Box 208058
New Haven, CT 06520-8058
United States
Appointments
Additional Titles
ERAS Lead, Urology
Homeostasis Course Lead, Urology
Faculty Lecture Series Contributor, Urology
Contact Info
Urology
PO Box 208058
New Haven, CT 06520-8058
United States
About
Titles
Associate Professor of Urology
ERAS Lead, Urology; Homeostasis Course Lead, Urology; Faculty Lecture Series Contributor, Urology
Biography
- Practice locations: New Haven, Hamden, Madison, Old Saybrook
- Residency: Yale New Haven Hospital, Yale School of Medicine, 2004
- Fellowship: Female Urology and Reconstructive Surgery, UCLA School of Medicine, 2006
- Clinical Interests: Urinary Incontinence (male and female) Urinary Tract Infection (female); Urinary Tract Infection (male), Overactive bladder, Neurogenic Bladder, Genitourinary Fistula, Robotic Surgery for Vaginal Prolapse, Transvaginal surgery for pelvic organ prolapse, Pelvic medicine, Physical therapy for pelvic floor disorders BPH: benign prostatic hypertrophy, urinary calculus-urolithiasis.
Mary Grey Maher, MD is board certified in both General Urology and Urogynecology.
Dr. Maher earned her undergraduate degree at Wellesley College, and her medical degree at Yale University. She completed her urology residency at Yale University School of Medicine, and Yale New Haven Hospital in 2004. After which, she spent an intensive year at UCLA, completing a fellowship in Female Pelvic Medicine and Reconstructive surgery with one of the founding fathers of Urogynecology, Dr. Shlomo Raz. She returned to her native Connecticut in 2006 to care for male and female patients suffering urinary incontinence, pelvic organ prolapse, benign prostate problems (BPH) and kidney stones.
Dr. Maher's clinical interests encompass overactive bladder, urinary incontinence, vaginal prolapse, male voiding dysfunction, incontinence and BPH, genitourinary reconstruction including repairing vesico-vaginal fistula. Additional areas of interest are hematuria, urinary tract infection, and kidney stones. She performs both the male sling and the male artificial urinary sphincter for post prostatectomy incontinence.
Dr. Maher employs a full range of treatment options to meet each patients' needs and wishes. She is patient-care focused and feels that it is critical to offer a range of treatment options: from conservative therapy with pelvic floor physical therapy, the Intone personal physical therapy devices, pessary placement, medication therapy, or an array of minimally invasive surgical procedures when indicated.
She also offers 'native or own tissue' repairs for patients who wish to avoid mesh in their surgical repairs. She has trained extensively in pelvic floor reconstruction and can offer a range of surgical repairs, customized to the patient’s condition and wishes, including robotic surgery. She provides innovative, and high quality care to help patients regain function and improve their quality of life.
Appointments
Urology
Associate Professor on TermPrimary
Other Departments & Organizations
- Lower Urinary Tract Dysfunction (LUTD) & Genitourinary Reconstruction
- Neurogenic Bladder Program
- Neurourology/Neurogenic Bladder
- Specialty Programs
- Urology
- Yale Medicine
Education & Training
- Fellowship
- University of California Los Angeles (2006)
- Residency
- Yale-New Haven Hospital (2004)
- Residency
- Yale-New Haven Hospital (2001)
- Internship
- Yale-New Haven Hospital (2000)
- MD
- Yale University School of Medicine (1999)
- BA
- Wellesley College, Philosophy, Biology (1989)
Research
Research at a Glance
Yale Co-Authors
Publications Timeline
Peter M. Glazer, MD, PhD
Robert M. Weiss, MD, FACS, FAAP
Ruth Halaban, PhD
Publications
2008
Chapter 47 SURGERY FOR REFRACTORY URINARY INCONTINENCE: SPIRAL SLING
Mourtzinos A, Maher M, Raz S, Rodríguez L. Chapter 47 SURGERY FOR REFRACTORY URINARY INCONTINENCE: SPIRAL SLING. 2008, 469-476. DOI: 10.1016/b978-1-4160-2339-5.50096-3.Peer-Reviewed Original ResearchChapter 41 DISTAL URETHRAL POLYPROPYLENE SLING
Zabihi N, Maher M, Rodríguez L. Chapter 41 DISTAL URETHRAL POLYPROPYLENE SLING. 2008, 430-434. DOI: 10.1016/b978-1-4160-2339-5.50090-2.Peer-Reviewed Original Research
2006
343: Under-Reporting of Major Complications of Sling Procedures
Deng D, Maher M, Mourtzinos A, Rutman M, Rodriguez L, Raz S. 343: Under-Reporting of Major Complications of Sling Procedures. Journal Of Urology 2006, 175: 112. DOI: 10.1016/s0022-5347(18)32599-0.Peer-Reviewed Original Research913: To Sling or not to Sling: Should Patients Undergoing a Grade IV Cystocele Repair Have a Prophylactic Anti-Incontinence Procedure
Mourtzinos A, Maher M, Zabihi N, Rodriguez L, Raz S. 913: To Sling or not to Sling: Should Patients Undergoing a Grade IV Cystocele Repair Have a Prophylactic Anti-Incontinence Procedure. Journal Of Urology 2006, 175: 295-296. DOI: 10.1016/s0022-5347(18)33149-5.Peer-Reviewed Original ResearchCitations1319: The Effects of Bilateral Caudal Epidural S2-4 Neuromodulation on Sexual Function
Zabihi N, Mourtzinos A, Maher M, Raz S, Rodriguez L. 1319: The Effects of Bilateral Caudal Epidural S2-4 Neuromodulation on Sexual Function. Journal Of Urology 2006, 175: 425. DOI: 10.1016/s0022-5347(18)33532-8.Peer-Reviewed Original Research908: Voiding Symptoms in Grade 4 Cystocele: Analysis of 350 Patients
Maher M, Mourtzinos A, Zabihi N, Laiwalla U, Raz S, Rodriguez L. 908: Voiding Symptoms in Grade 4 Cystocele: Analysis of 350 Patients. Journal Of Urology 2006, 175: 294. DOI: 10.1016/s0022-5347(18)33144-6.Peer-Reviewed Original ResearchCitations
2002
Bladder cancer detection with urinary survivin, an inhibitor of apoptosis.
Sharp JD, Hausladen DA, Maher MG, Wheeler MA, Altieri DC, Weiss RM. Bladder cancer detection with urinary survivin, an inhibitor of apoptosis. Frontiers In Bioscience-Landmark 2002, 7: e36-41. PMID: 11815300, DOI: 10.2741/sharp.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsMeSH KeywordsApoptosisBiomarkersCarcinoma, Transitional CellChromosomal Proteins, Non-HistoneCystoscopyCytodiagnosisHumansImmunoblottingInhibitor of Apoptosis ProteinsMicrotubule-Associated ProteinsNeoplasm ProteinsNeoplasm Recurrence, LocalSensitivity and SpecificitySurvivinUrinary Bladder Neoplasms
1998
Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways.
Turner B, Zhang J, Gumbs A, Maher M, Kaplan L, Carter D, Glazer P, Hurst H, Haffty B, Williams T. Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways. Cancer Research 1998, 58: 5466-72. PMID: 9850080.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsMeSH KeywordsBinding SitesBreastBreast NeoplasmsDNA-Binding ProteinsEpitheliumFemaleHumansImmunohistochemistryPrognosisPromoter Regions, GeneticReceptor, ErbB-2Receptor, IGF Type 1Receptors, EstrogenReceptors, Growth FactorReceptors, ProgesteroneSignal TransductionTranscription Factor AP-2Transcription FactorsTumor Cells, CulturedUp-RegulationConceptsAP-2 transcription factorsAP-2-binding sitesTranscription factorsAP-2gammaAP-2alphaAP-2 gene familyAP-2 geneAP-2 family membersInsulin-like growth factor I receptorAP-2 familySignal transduction moleculesAP-2 proteinsAP-2alpha proteinMammalian developmentGene familyHuman breast cancerGrowth factor receptorTransduction moleculesProximal promoterBreast cancerReceptor promoterMultiple growth factorsBreast cancer cell linesCell growthAP-2gamma expressionPrognostic significance of colony-stimulating factor receptor expression in ipsilateral breast cancer recurrence.
Maher M, Sapi E, Turner B, Gumbs A, Perrotta P, Carter D, Kacinski B, Haffty B. Prognostic significance of colony-stimulating factor receptor expression in ipsilateral breast cancer recurrence. Clinical Cancer Research 1998, 4: 1851-6. PMID: 9717811.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsIpsilateral breast tumor recurrenceCSF-1R antibodyCSF-1R expressionIpsilateral breast cancer recurrenceBreast tumor recurrenceBreast cancer patientsBreast cancer recurrencePoor prognostic roleColony-stimulating factor receptor expressionCSF-1RFactor receptor expressionEarly stage IBreast carcinoma cellsDifferentiation of macrophagesConservative surgeryControl patientsLocal relapseNodal statusPrognostic roleDistant metastasisClinical stagePrognostic significanceCancer patientsTumor recurrenceCancer recurrence
1997
Recognition of activated CSF-1 receptor in breast carcinomas by a tyrosine 723 phosphospecific antibody
Flick M, Sapi E, Perrotta P, Maher M, Halaban R, Carter D, Kacinski B. Recognition of activated CSF-1 receptor in breast carcinomas by a tyrosine 723 phosphospecific antibody. Oncogene 1997, 14: 2553-2561. PMID: 9191055, DOI: 10.1038/sj.onc.1201092.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAmino Acid SequenceAnimalsAntibodiesAntibody SpecificityBreast NeoplasmsCarcinoma in SituCells, CulturedCross ReactionsEpitopesFibroblastsGenes, fmsHumansImmunohistochemistryMacrophagesMiceMice, Inbred BALB CPhosphopeptidesPhosphorylationPhosphotyrosineProto-Oncogene MasReceptor, Macrophage Colony-Stimulating FactorTumor Cells, CulturedConceptsCSF-1RMultiple signal transduction pathwaysC-fms proto-oncogenePhosphorylation state-specific antibodiesSignal transduction pathwaysCSF-1 receptorAnchorage-independent growthImmunoblots of lysatesActivation/phosphorylationEffector proteinsVivo phosphorylationCytoplasmic domainDifferentiation of macrophagesPhosphospecific antibodiesTransduction pathwaysCellular phenotypesInvasive human breast tumoursSpecific phosphopeptidesC-fms oncogeneCSF-1Proto-oncogeneHuman breast carcinomaFirst direct evidenceNormal proliferationFactor receptor
Academic Achievements & Community Involvement
activity "Subjective and Objective Voiding Dysfunction in Grade 4 Cystocele: Analysis of 350 Patients."
Oral Presentation"Subjective and Objective Voiding Dysfunction in Grade 4 Cystocele: Analysis of 350 Patients."Details09/28/2006 - 09/30/2006Providence, RI, United StatesSponsored by American Urological AssociationAbstract/SynopsisPresentation given at the 75th Annual Meeting of the New England Section of the American Urological Association
activity “Voiding Symptoms in Grade 4 Cystocele: Analysis of 350 Patients.”
Oral Presentation"Voiding Symptoms in Grade 4 Cystocele: Analysis of 350 Patients."Details05/20/2006 - 05/25/2006Atlanta, GA, United StatesSponsored by American Urological AssociationAbstract/SynopsisPodium Session at the Annual Meeting of the American Urological Association
activity “Bilateral-Caudal-Epidural Neuromodulation for Refractory Urinary Retention: A Salvage Procedure.”
Oral Presentation“Bilateral-Caudal-Epidural Neuromodulation for Refractory Urinary Retention: A Salvage Procedure.”Details02/22/2006 - 02/25/2006Nassau, New Providence, BahamasSponsored by Society for Urodynamics and Female UrologyAbstract/SynopsisPresentation given at the XXYY Annual Meeting of Society for Urodynamics and Female Urology
activity “Fluorescence in situ Hybridization (FISH): Improved Sensitivity for Atypical Urine Cytology.”
Oral Presentation“Fluorescence in situ Hybridization (FISH): Improved Sensitivity for Atypical Urine Cytology.”Details01/01/2003 - 12/31/2003Mont-Tremblant, QC, CanadaSponsored by American Urological AssociationAbstract/SynopsisPresentation given at the 72nd Annual Meeting of The New England Section of the American Urological Association
Clinical Care
Overview
Mary Grey Maher, MD, is board-certified in both general urology and urogynecology, a specialty focused on conditions that affect the female pelvic organs.
Dr. Maher’s interests include overactive bladder, urinary incontinence, vaginal prolapse, male voiding dysfunction, urinary tract infection, and kidney stones. She performs both the male sling and the male artificial urinary sphincter for post prostatectomy incontinence(which can occur after prostate cancer surgery).
Dr. Maher believes providing her patients with multiple treatment options is key. For example, if her patients want to avoid mesh for required surgical repairs, she offers native tissue repairs. She’s also trained extensively in pelvic floor reconstruction and can provide a range of approaches to surgical repair, including robotic surgery.
She is an associate professor of clinical urology at Yale School of Medicine.
Clinical Specialties
Fact Sheets
Overactive Bladder
Learn More on Yale MedicineNeurogenic Bladder and Incontinence
Learn More on Yale MedicineUrinary Retention
Learn More on Yale MedicineStress Incontinence
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- June 24, 2024
2024 Yale Urology Graduation Awards
- June 20, 2024
Congratulations MHS-Med Ed Graduates & Medical Education Fellows!
- May 02, 2024
14 Yale Urology Physicians Named "Top Doctors" For 2024
- October 04, 2023
Bulldog Debates Recap
Get In Touch
Contacts
Urology
PO Box 208058
New Haven, CT 06520-8058
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.